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The pneumococcal pilus has been shown to be an important determinant of adhesion and virulence in mouse models of coloni-
zation, pneumonia, and bacteremia. A pilus is capable of inducing protective immunity, supporting its inclusion in next-genera-
tion pneumococcal protein vaccine formulations. Whether this vaccine target is common among pneumococci in sub-Saharan
Africa is uncertain. To define the prevalence and genetic diversity of type I and II pili among invasive pneumococci in Malawi
prior to the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) into routine childhood immunization, we
examined 188 Streptococcus pneumoniae isolates collected between 2002 and 2008 (17% serotype 1). In this region of high dis-
ease burden, we found a low frequency of invasive piliated pneumococci (14%) and pilus gene sequence diversity similar to that
seen previously in multiple global pneumococcal lineages. All common serotypes with pilus were covered by PCV13 and so we
predict that pilus prevalence will be reduced in theMalawian pneumococcal population after PCV13 introduction.
Streptococcus pneumoniae is a prominent vaccine-preventablecause of pneumonia, meningitis, septicemia, and acute otitis
media worldwide (1). A frequent commensal of the upper respi-
ratory tract, S. pneumoniae possesses a range of factors that facil-
itate nasopharyngeal colonization by enhancing host cell attach-
ment and that have also been implicated in the pathogenesis of
invasive pneumococcal disease (IPD) (2, 3). These include pilus-
like structures that are also assembled on the surfaces of a range of
other Gram-positive bacteria, including: Actinomyces naeslundii,
Corynebacterium diphtheriae, Streptococcus parasanguinis, group
A Streptococcus, group B Streptococcus, and Mycobacterium tuber-
culosis (4–8). Currently, two types of functional pneumococcal
pili (type I and type II) encoded by several different gene subunits
have been identified (8, 9), and there is evidence that pilus gene
subunits are acquired through horizontal gene transfer in many
streptococci and other Gram-positive pathogens (10). The TIGR4
pneumococcal strain pilus appears to be an important determi-
nant of adhesion and virulence in C57BL/6 mouse models of
pneumococcal colonization, pneumonia, and bacteremia (8). A
previous study demonstrated that nasopharyngeal cocolonization
with Staphylococcus aureus was 2-fold lower in children aged40
months carrying a piliated strain than in those carrying a nonpili-
ated strain, suggesting that piliated pneumococcal strains may di-
minish nasopharyngeal cocolonization by outcompeting their
niche competitors (11).
Studies in Europe, North America, and Israel have shown pili
to be prevalent in up to 30% of invasive pneumococci; however,
piliated strains that are geographically distinct are yet to be iden-
tified (12–14). The apparent role of the pneumococcal pilus as an
important mediator of host-bacterial interactions has led to its
consideration as a part of a multicomponent second-generation
serotype-independent vaccine that is currently undergoing evalu-
ation (8, 15). Immunization with recombinant TIGR4 pneumo-
coccal pilus subunits and passive transfer of antisera raised against
pili are protective in BALB/c mouse models of infection (16).
However, it has recently been shown that the frequency of piliated
pneumococcal strains changes after pneumococcal conjugate vac-
cine (PCV) introduction (13, 17). Following 7-valent pneumo-
coccal conjugate vaccine (PCV7) implementation in the United
States in 2000 (15, 18), there was initially a marked decrease in
circulating vaccine type (VT) serotypes, including piliated VT
strains, which was then followed by an increase of piliated poten-
tially invasive nonvaccine type (NVT) serotypes (12, 13, 15).
Moreover, the association between the type I pilus and antimicro-
bial resistance (12) raises concern that PCV introduction may lead
to a widespread increase in piliated NVT antibiotic-resistant
pneumococci. These piliated NVT antibiotic-resistant strains
would potentially promote efficient pneumococcal transmission
by enhancing initial colonization and outcompeting cocolonizing
niche competitors, thereby facilitating invasive disease in both
PCV-vaccinated and immunocompromised populations.
Given the high burden of pneumococcal carriage and invasive
pneumococcal disease, we sought to investigate the prevalence of
piliated pneumococci in Malawi, a resource-poor sub-Saharan
African country (19–22). We further speculated that in view of the
high frequency of immunocompromised PCV-vaccine-naive in-
dividuals, pili from this region could be genetically diverse com-
pared to those studied from elsewhere. We therefore examined
pilus prevalence and genetic diversity among a set of invasive iso-
lates collected from patients presenting to a large district and ter-
tiary referral hospital in Malawi prior to PCV13 introduction.
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MATERIALS AND METHODS
Strain selection. A total of 188 S. pneumoniae isolates cultured from ce-
rebral spinal fluid (CSF) (n 93) and blood (n 95) from children (n
96) and adults (n  92) between 2002 and 2008 were randomly selected
using STATA v 9.2 (Stata Corp., College Station, TX) from the invasive
isolate collection of the Malawi-Liverpool-Wellcome Trust Clinical Re-
search Programme (20). Isolates had been stored at80°C after primary
isolation in bead and broth cryopreservers (Pro-Lab Diagnostics, Rich-
mond Hill, ON, Canada). Collection of these data was approved by the
University of Malawi College of Medicine Research & Ethics Committee
and conforms to institutional guidelines.
Microbiologic processing and DNA extraction and sequencing.
Prior to DNA extraction, strains were grown overnight on gentamicin
blood agar plates with optochin discs at 37°C in 5% CO2. S. pneumoniae
was identified by colony morphology, -hemolysis, and optochin suscep-
tibility as previously described (20). Antibiotic susceptibilities, deter-
mined on all isolates by disc diffusion testing (Oxoid, United Kingdom)
using the British Society for Antimicrobial Chemotherapy (BSAC) sensi-
tivity method for direct cultures, were used to categorize isolates as either
antibiotic nonsusceptible or susceptible to common clinically prescribed
antibiotics as previously described (20).
A single colony from each primary culture plate was subcultured over-
night on a plate of blood agar, at 37°C in 5% CO2. The pure colonies were
transferred into 15 ml of Todd-Hewitt broth (Oxoid Limited, Basing-
stoke, Hampshire, England) and cultured overnight at 37°C in 5% CO2.
The overnight culture was pelleted by centrifugation (13,000  g for 3.5
min). The supernatant was discarded and DNA extracted using a modi-
fied Wizard genomic DNA purification kit (Promega, Madison, WI), as
previously described (23). Samples were diluted to 2.5 g in 100 l Tris-
EDTA buffer followed by multiplex library construction, with a 200-bp
insertion size, and 54-nucleotide (nt) paired-end Illumina Genome Ana-
lyzer GAII (Illumina, CA, USA) sequencing.
FIG 1 Distribution of pilus subunits for each of the type I and II piliated strains. (A) The type I pilus subunits are flanked by transposase genes (blue). The missing
pilus subunits are indicated in white. Pilus subunits of strains associated with bacteremia are indicated in orange, and those found in strains associated with
meningitis are indicated in light blue. (B) The type II pilus subunits are flanked by the PepT and HemH genes (green). The missing pilus subunits are indicated
in white. Pilus subunits of strains associated with bacteremia are indicated in light orange, and those found in strains associated with meningitis are indicated in
light blue. Two serotype 19F isolates had both type I and II pilus subunits simultaneously present, and these were strains 2 (unique strain identification [ID], A2)
and 10 (unique strain ID, A10) in the type I pilus data set corresponding to strains 1 (unique strain ID, A2) and 10 (unique strain ID, A10) in the type II pilus data
set, respectively. ST, sequence type.
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Assembly of draft genomes and detection of the pilus operon. De
novo assembly of draft genome sequences was achieved from multiplexed
Illumina sequence data using Velvet (version 0.7.03) (24), ordered against
the S. pneumoniae ATCC 700669 genome using ABACAS (25), and then
annotated using Glimmer3 (26). Annotations from 12 publicly available,
complete, fully annotated reference genomes were transferred onto the
draft genomes through a process of clustering using OrthoMCL (27) with
default parameters, thereby allowing identification of the pilus operon.
Determination of serotype and sequence type. Serotype and se-
quence type (ST) data were derived from genome sequences using previ-
ously described protocols (28). Briefly, the sequences of 94 pneumococcal
cps loci were concatenated and Illumina sequence reads redundantly
aligned against this reference using BWA (29). The capsular locus with the
largest segments of its length covered by mapped sequence reads was
considered to be that encoding the capsule, enabling the serotype to be
identified.
The sequences of the seven loci used for sequence typing, along with
several hundred base pairs of the flanking sequence, were obtained either
from the genome of S. pneumoniae ATCC 700669 (EMBL accession num-
ber FM211187) or S. pneumoniae OXC141 (EMBL accession number
FQ312027). Five passes of Illumina read mapping were then used to iter-
atively transform the reference sequences into those of the sequenced
isolate using ICORN (30). The sequences were then analyzed using the
MLST nucleotide sequence database (www.mlst.net) (31) to establish se-
quence types. All novel unassigned sequence types were labeled “un-
known.”
Sequence alignment and phylogeny reconstruction. The pilus sub-
unit sequences of each of the isolates were concatenated into single se-
quences. Multiple sequence alignments were performed using MUSCLE
(32). The maximum-likelihood (ML) phylogenetic analysis of multiple
aligned sequences with bootstrap values for 100 bootstrap replicates was
performed using PhyML (version 3.5) (33).
Statistical analysis. All statistical analyses were performed using
STATA v 9.2 (Stata Corp., College Station, TX). Fisher’s exact P value
statistics were used to test the null hypothesis of independence.
Nucleotide sequence accession numbers. All of the GAII reads gen-
erated are deposited in the short read archive (National Centre for Bio-
technology Information) under the accession numbers ERP000185 and
ERP000152.
RESULTS
Prevalence of the pilus operon in S. pneumoniae.Type I and type
II pilus subunits were detected by the process of clustering or-
thologous gene sequences using OrthoMCL (27). Overall, al-
though 20% had detectable genes coding pilus subunits, only 14%
of the pneumococcal strains had complete pilus subunit gene sets
and were therefore capable of pilus assembly and were considered
for further analysis. We detected 9% (17/188) and 6% (11/188) of
the strains with complete type I and II pilus subunit gene sets,
respectively, and two serotype 19F strains; 1% (2/188) had both
type I and type II (Fig. 1). This cooccurrence has previously been
reported (14). Incomplete pilus genes incapable of pilus assembly
were likely to be a result of sequencing errors or poor sequence
assembly, and we speculate that they may also have resulted from
the acquisition of incomplete sets of pilus gene subunits during
recombination, which has previously been described in Neisseria
gonorrhoeae (10, 34–36). Type I pilus subunits spanned 5 STs (172,
347, 802, 5412, and 5778), covering 7 serotypes (4, 6A, 9A, 15C,
19A, 19F, and 23F), whereas type II pilus subunits were identified
in a different set of 3 STs (347, 3544, and 5778), covering 4 differ-
ent serotypes (1, 7A, 7F, 9A, and 19F). Type I and II pilus subunits
were also identified in pneumococci with novel unassigned STs,
labeled as “Unknown” (UK) (n  23), yet to be classified on the
multilocus sequence typing database (www.mlst.net) (Fig. 1).
Associationofpilusoperonwith serotype, genotype, age, and
disease outcome. Although pili were present in a minority of
strains (Fig. 2), all of these serotypes are covered by the 13-valent
FIG 2 Distribution of piliated Streptococcus pneumoniae by serotype. The histograms show the frequency of type I piliated (black), type II piliated (gray),
nonpiliated (white), and both type I and type II piliated (striped) isolates in our collection, stratified by serotypes. The PCV13 vaccine contains polysaccharides
of the capsular antigens of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, individually conjugated to a nontoxic
diphtheria CRM197 carrier protein. Serotypes included in the PCV13 are marked with a black dot (), while those cross protected are indicated with a triangle
(o). The PCV13 vaccine provides coverage for piliated invasive pneumococci in Malawi.
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pneumococcal conjugate vaccine (PCV13) except 7A and 9A,
which are cross protected through the inclusion of serotypes 7F
and 9V in the vaccine (23). There was no relationship between
strain piliation and ST. There was no association between pilus
type and either adults (type I, 9/92, and type II, 5/92) or children
(type I, 8/96, and type II, 6/96) (Fisher’s exact P values of 0.8 and
1.0, respectively). The pilus genes were equally common in pili-
ated blood and CSF isolates, with 64.7% (11/17) type I CSF pili-
ated (Fisher’s exact P value of 0.2) and 54.5% (6/11) type II blood
piliated (Fisher’s exact P value of 1.0) pneumococci.
Association of pilus operonwith antibiotic susceptibility.To
examine whether antibiotic-nonsusceptible pneumococci were
more likely to carry pili, 3 commonly used antibiotics were stud-
ied, tetracycline, chloramphenicol, and co-trimoxazole (resis-
tance to penicillin is uncommon in Malawi). We noted a slightly
disproportionate fraction of co-trimoxazole-nonsusceptible pili-
ated pneumococci, compared to those of chloramphenicol and
tetracycline (Fig. 3), suggesting a possible association between the
pilus and co-trimoxazole nonsusceptibility. However, compari-
sons between the piliated (types I and II) and nonpiliated strains
showed no significant differences in co-trimoxazole nonsuscepti-
bility (Fisher’s exact P values of 0.11 and 0.2 for types I and II,
respectively).
Pilus operon sequence diversity. We assessed sequence diver-
sity of the two pili among the 188 invasive strains and compared
them to the well-characterized reference type I pilus sequences
from the Pneumococcal Molecular Epidemiology Network
(PMEN) collection (GenBank accession numbers EF560625
through EF560637) and a publically available type II pilus se-
quence (GenBank accession number GU256423). The phyloge-
netic analysis of the pilus loci classified the type I pilus sequences
into 3 main clades (Fig. 4A), while the type II pilus sequences were
classified into 2 clades (Fig. 4B). This indicated that the type I pili
in pneumococci circulating in Malawi were genetically closely re-
lated to those identified in the global Pneumococcal Molecular
Epidemiology Network collection, previously classified into 3
main clades based on nucleotide sequence diversity (12). A single
strain bearing a genetically diverse type II nucleotide sequence
highlights the likelihood of more than one clade of type II pneu-
mococcal pili.
DISCUSSION
The TIGR4 pneumococcal pilus has been demonstrated to en-
hance initial adhesion, thereby conferring a specific colonization
advantage (8), and diminished nasopharyngeal cocolonization by
other niche competitors has been attributed to pneumococcal
piliation (11). In this study, the prevalence of pneumococci with
pilus gene subunits prior to PCV13 introduction in Malawi was
relatively low (14%) and lower than that reported elsewhere (11,
13, 15). This low prevalence was not explained by the dominance
of a single serotype, indeed pilus subunits were present across a
number of serotypes (37) covered by the 13-valent pneumococcal
FIG 3 Distribution of antibiotic susceptibility to tetracycline, co-trimoxazole, and chloramphenicol among type I and II piliated invasive pneumococci. The
histograms show the number of type I piliated, type II piliated, and nonpiliated invasive pneumococcal strains susceptible to chloramphenicol, tetracycline, and
co-trimoxazole. Significant differences in proportions of pneumococcal strains susceptible to each antibiotic between groups (type I, type II, and nonpiliated)
were evaluated. Although the proportions of co-trimoxazole-nonsusceptible piliated strains appeared pronounced relative to tetracycline- and chloramphenicol-
nonsusceptible strains, they were not significantly different from those of nonpiliated strains (Fisher’s exact P values of 0.11 and 0.2 for types I and II,
respectively).
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conjugate vaccine (PCV13) either directly or through cross pro-
tection. These data suggest that the addition of a pneumococcal
pilus to a multicomponent second-generation serotype-indepen-
dent vaccine would offer little additional protective benefit in sub-
Saharan African countries like Malawi.
We observed no association between pilus presence and anti-
biotic nonsusceptibility. Co-trimoxazole prophylaxis for HIV-in-
fected individuals was introduced in Malawi in 2002 and became a
government policy in 2005 (20). Until recently, sulfadoxine-pyri-
methamine (Fansidar) was widely used to treat malaria (as with
co-trimoxazole, it targets dihydrofolate reductase and dihydrop-
teroate synthase). The percentage of invasive pneumococci non-
susceptible to co-trimoxazole has increased steadily in Malawi
since 2002 (20). Whether and how the use of co-trimoxazole and
sulfadoxine-pyrimethamine has driven the emergence of piliated
antibiotic-resistant pneumococci and whether this relates to the
FIG 4 Genetic variability among types I and II pili in Streptococcus pneumoniae. Each strain is labeled using its ST (unknown STs are labeled “ST UK”) or PMEN
name (for the global collection pneumococcal pilus genes) and serotype. The type II reference strain is labeled as “reference.” (A) Type I pilus sequences were
associated with 3 main clades, labeled clades 1, 2, and 3 according to a previously described naming convention (12). (B) Type II pilus sequences were associated
with 2 clades, labeled clades 1 and 2. There was very little sequence diversity between the reference strain and the Malawian strains.
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specific colonization advantage conferred by pili remain to be de-
termined. While this study was limited to convenient sampling
from a retrospective data subset of invasive disease pneumococcal
isolates, others have made observed associations between antibi-
otic nonsusceptibility and pilus presence (12).
Type I pili have previously been categorized into 3 main clades
using a global pneumococcal collection (12). In this study, type I
pili were also classified into 3 main clades, whereas 2 clades of type
II pili were observed. This implies that pneumococcal pili identi-
fied in Malawi, an African country with a high disease burden,
have the same antigenic diversity as those described from other
continents. The lower number of clades in type II pilus subunits
implies that they are genetically less diverse than those of type I.
There was no clear association between pilus diversity and STs,
suggesting that pilus sequence diversity was not associated with
specific pneumococcal genotypes but is acquired through recom-
bination and maintained or lost during clonal diversification (12).
We acknowledge that our study may have been limited by conve-
nient sampling from a retrospective data subset of invasive disease
pneumococcal isolates; however, this does not detract from the
main point that the diversity of pili in Malawian invasive pneu-
mococcal isolates was similar to that of pili previously described
from other continents. Future studies will include larger data sets
of both invasive and carriage isolates.
In conclusion, the prevalence of piliated invasive pneumococ-
cal strains is markedly lower in this high-carriage and high-inva-
sive-disease-burden environment than in industrialized coun-
tries. When pili were present, the serotypes containing pili were all
covered by PCV13. Therefore, unless marked capsule switching
occurs, clonal expansion of invasive nonvaccine piliated serotypes
is unlikely to occur after PCV13 introduction in countries such as
Malawi. Nonetheless, there is a need for continued surveillance
after vaccine introduction to fully understand the impact on pilus
prevalence in this setting.
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